Company: YCY-WT
Filing Date: 2025-07-09
Form Type: DRS
Source: 0001213900-25-062426
Chunk: 84

Company: AA Mission Acquisition Corp. II
Filing Date: 2025-07-09
Form: DRS
Chunk 84
---
 responsibilities, the audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors, or our or their affiliates and monitor compliance with the other terms relating to this offering. If any noncompliance is identified, then the audit committee will be charged with the responsibility to promptly take all action necessary to rectify such noncompliance or otherwise to cause compliance with the terms of this offering. For more information, see the section entitled “Management — Committees of the Board of Directors — Audit Committee.” |

49

Dilution The difference between the public offering price per unit and the net tangible book value (“NTBV”) per ordinary share after this offering constitutes the dilution to investors in this offering. NTBV per share is determined by dividing our NTBV, which is our total tangible assets less total liabilities (including the value of ordinary shares that may be redeemed for cash), by the number of outstanding ordinary shares. See the section “ Dilution.” The below calculations (A) assume that (i) no ordinary shares are issued to shareholders of a potential business combination target as consideration or issuable by a post -businesscombination company, for instance under an equity or employee share purchase plan, (ii) no ordinary shares and convertible equity or debt securities are issued in connection with additional financing that we may seek in connection with an initial business combination, (iii) no working capital notes are converted into private placement units, as further described in this prospectus, (iv) no value is attributed to the warrants (however, we may need to issue ordinary shares or convertible equity in the circumstances described above, as we intend to target an initial business combination with a target company whose enterprise value is greater than the next proceeds of this offering and the sale of private placement units) and (v) the anti -dilutionprovision applicable to the Class B shares do not impact the dilution calculations in the proforma presentation, and (B) assume the issuance of 10,000,000 public shares (or 11,500,000 public shares if the over -allotmentoption is exercised in full), 2,875,000 founder shares (up to 375,000 of which are assumed to be forfeited in the scenario in which the over -allotmentoption is not exercised in full). Such calculations do not reflect any dilution associated with the exercise of warrants as the warrants are only exercisable at the later of one (1) year after the date of the closing of this offering and upon the